Immunotherapy in Hodgkin Lymphoma: The Road Ahead

被引：17

作者：

Ansell, Stephen M. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, 200 First St, Rochester, MN 55905 USA

来源：

TRENDS IN IMMUNOLOGY | 2019年 / 40卷 / 05期

关键词：

REED-STERNBERG CELLS; BRENTUXIMAB VEDOTIN; PHASE-II; ANALYSIS REVEALS; PD-1; BLOCKADE; NIVOLUMAB; DISEASE; TRANSPLANTATION; CHEMOTHERAPY; THERAPY;

D O I：

10.1016/j.it.2019.03.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An extensive infiltrate of intratumoral immune cells is a hallmark of classic Hodgkin lymphoma (cHL) but these cells do result in an effective antitumor response. Immune checkpoint therapy, which activates 'exhausted' T cells, has been found to be highly effective in cHL, but responding patients commonly relapse. Combination approaches are currently being investigated but the assessment of benefit when adding immunotherapy is challenging. The pitfalls in designing combination studies derive from response endpoints that are difficult to measure, a lack of biomarkers that predict response, and a limited understanding of tumor biology. While progress in treating patients with cHL has been exceptional so far, further progress may require a review of clinical trial endpoints and a greater understanding of cHL biology.

引用

页码：380 / 386

页数：7

共 36 条

[21] Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma [J].

Green, Michael R. ;

Monti, Stefano ;

Rodig, Scott J. ;

Juszczynski, Przemyslaw ;

Currie, Treeve ;

O'Donnell, Evan ;

Chapuy, Bjoern ;

Takeyama, Kunihiko ;

Neuberg, Donna ;

Golub, Todd R. ;

Kutok, Jeffery L. ;

Shipp, Margaret A. .

BLOOD, 2010, 116 (17) :3268-3277

[22] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma [J].

Herrera, Alex F. ;

Moskowitz, Alison J. ;

Bartlett, Nancy L. ;

Vose, Julie M. ;

Ramchandren, Radhakrishnan ;

Feldman, Tatyana A. ;

LaCasce, Ann S. ;

Ansell, Stephen M. ;

Moskowitz, Craig H. ;

Fenton, Keenan ;

Ogden, Carol Anne ;

Taft, David ;

Zhang, Qu ;

Kato, Kazunobu ;

Campbell, Mary ;

Advani, Ranjana H. .

BLOOD, 2018, 131 (11) :1183-1194

[23] Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma [J].

Jalali, Shahrzad ;

Price-Troska, Tammy ;

Bothun, Cole ;

Villasboas, Jose ;

Kim, Hyo-Jin ;

Yang, Zhi-Zhang ;

Novak, Anne J. ;

Dong, Haidong ;

Ansell, Stephen M. .

BLOOD CANCER JOURNAL, 2019, 9 (3)

[24] Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia [J].

Jalali, Shahrzad ;

Price-Troska, Tammy ;

Paludo, Jonas ;

Villasboas, Jose ;

Kim, Hyo-Jin ;

Yang, Zhi-Zhang ;

Novak, Anne J. ;

Ansell, Stephen M. .

BLOOD ADVANCES, 2018, 2 (15) :1985-1997

[25] Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells [J].

Kanzler, H ;

Kuppers, R ;

Hansmann, ML ;

Rajewsky, K .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (04) :1495-1505

[26] Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling [J].

Liu, Hongbin ;

Hu, Yunshan ;

Rimoldi, Rafael ;

Von Hagt, Chloe ;

Khong, Edmund W. C. ;

Lee, Nora ;

Flemming, Shaun ;

Spencer, Andrew ;

Dear, Anthony E. .

ONCOLOGY LETTERS, 2019, 17 (02) :2543-2550

[27] A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression [J].

Mahoney, Kathleen M. ;

Shukla, Sachet A. ;

Patsoukis, Nikolaos ;

Chaudhri, Apoorvi ;

Browne, Edward P. ;

Arazi, Arnon ;

Eisenhaure, Thomas M. ;

Pendergraft, William F., III ;

Hua, Ping ;

Pham, Hung C. ;

Bu, Xia ;

Zhu, Baogong ;

Hacohen, Nir ;

Fritsch, Edward F. ;

Boussiotis, Vassiliki A. ;

Wu, Catherine J. ;

Freeman, Gordon J. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (03) :421-432

[28] PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study [J].

Moskowitz, Alison J. ;

Schoeder, Heiko ;

Yahalom, Joachim ;

McCall, Susan J. ;

Fox, Stephanie Y. ;

Gerecitano, John ;

Grewal, Ravinder ;

Hamlin, Paul A. ;

Horwitz, Steven ;

Kobos, Rachel ;

Kumar, Anita ;

Matasar, Matthew ;

Noy, Ariela ;

Palomba, M. Lia ;

Perales, Miguel-Angel ;

Portlock, Carol S. ;

Sauter, Craig ;

Shukla, Neerav ;

Steinherz, Peter ;

Straus, David ;

Trippett, Tanya ;

Younes, Anas ;

Zelenetz, Andrew ;

Moskowitz, Craig H. .

LANCET ONCOLOGY, 2015, 16 (03) :284-292

[29] Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma [J].

Roemer, Margaretha G. M. ;

Redd, Robert A. ;

Cader, Fathima Zumla ;

Pak, Christine J. ;

Abdelrahman, Sara ;

Ouyang, Jing ;

Sasse, Stephanie ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Ansell, Stephen ;

Kato, Kazunobu ;

Farsaci, Benedetto ;

Sumbul, Anne ;

Armand, Philippe ;

Neuberg, Donna S. ;

Pinkus, Geraldine S. ;

Ligon, Azra H. ;

Rodig, Scott J. ;

Shipp, Margaret A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (10) :942-+

[30] PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome [J].

Roemer, Margaretha G. M. ;

Advani, Ranjana H. ;

Ligon, Azra H. ;

Natkunam, Yasodha ;

Redd, Robert A. ;

Homer, Heather ;

Connelly, Courtney F. ;

Sun, Heather H. ;

Daadi, Sarah E. ;

Freeman, Gordon J. ;

Armand, Philippe ;

Chapuy, Bjoern ;

de Jong, Daphne ;

Hoppe, Richard T. ;

Neuberg, Donna S. ;

Rodig, Scott J. ;

Shipp, Margaret A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (23) :2690-+

← 1 2 3 4 →